Biotechnology - Licensing, Bayer

Filter

Current filters:

LicensingBayer

Popular Filters

Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

23-06-2014

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with…

BayerBiotechnologyDimension TheapeuticsHematologyLicensingResearch

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer

17-02-2014

X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…

BayerBiotechnologyLicensingOncologyX-Chem

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Bayer to spend up to $520 million on antibody drug conjugate deal with Seattle Genetics

26-06-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) says it has entered into a new antibody-drug conjugate…

BayerBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

KYTHERA Biopharma gets $33.3 million in payments from Bayer

07-06-2012

Privately-held US biotech firm KYTHERA Biopharmaceuticals says it has received a $15.8 million payment…

BayerBiotechnologyFinancialKYTHERA BiopharmaceuticalsLicensingPharmaceuticalResearch

Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development

05-06-2012

Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner…

BayerBioInventBiotechnologyLicensingOncologyOphthalmicsPharmaceuticalRocheTB-402TB-403ThromboGenicsXarelto

Back to top